Exploring new pMDI propellants for a greener future
There is a need to adopt more environmentally friendly pMDI propellants, not only to reduce carbon footprint, but also to mitigate supply issues that may result from the decline in the use of existing propellants. It is critical that drug developers and manufacturers prepare their facilities for the use of these propellants, considering factors such as container closure compatibility, flammability, and challenges in process development and scale-up. Those who prepare now can help “future-proof” their operations, continuing to bring pMDIs to patients who depend on them.
While exploring the potential industry changes around the application of existing propellants, companies need to actively work to prepare so that they can tackle these hurdles head on.
Hydrofluorocarbons (HFAs) or F-gases have been shown to have an impact on global warming due to their high Global Warming Potential (GWP) and long atmospheric life (AL). However, recent research shows there is an aim to phase down global HFA consumption. This decision will no doubt affect the inhalation industry and respiratory healthcare sectors where pressurised metered dose inhalers (pMDIs) utilising HFAs as propellants are produced and prescribed
In an article with Inhalation Magazine, Lei Mao, Ph.D., Director of Inhalation Science and Product Development, Ron Roscher, Head of Engineering and HSE and Mark Knowles, Head of Product Engineering at Recipharm discuss how the inhalation industry should be prepared and ready to adopt new propellants to guarantee the continued, reliable manufacture and supply of vital medicines.
Click here to read more.